The effects on HF prevention were more pronounced in studies restricted to patients with atherosclerotic cardiovascular disease and in trials with higher incidence rate of HF events.<h4>Conclusion</h4>Treatment with GLP-1 RA decreases the risk of new-onset HF in patients with Type 2 diabetes or obesity. The gene discussed is GLP1R; the disease is Obesity.